The U.S. Food and Drug Administration on Sept. 23 approved lirafugratinib, a once-daily pill sold as Lyrfigtu, for adults with advanced bile duct cancer whose tumors carry an FGFR2 gene fusion or other rearrangement and who have already received treatment, OncLive reported.
Bile duct cancer, or cholangiocarcinoma, is rare, with about 8,000 new U.S. diagnoses each year, according to the American Cancer Society. It is often found late, when surgery is no longer possible. FGFR2 fusions or rearrangements appear in roughly 10% to 15% of cancers that start in the bile ducts inside the liver, Oncology Nursing News reported, so the approval applies to a small but seriously ill group.
